P
ProHub
English 简体中文 繁體中文
Medium Merger & Acquisition Profitability

OncoCo

#Healthcare
ProHub Comment

This is a multi-layered M&A case requiring candidates to first diagnose why OncoCo's core business is declining (patent expiration and generic entry), then evaluate whether acquiring liquid morphine commercial rights is strategically sound. The case tests financial analysis, market sizing, and qualitative strategic judgment—the key insight is that high EBITDA margins alone don't justify an acquisition if the business model mismatch and reputational risks are substantial.

Estimated Time 27 minutes
Difficulty Medium
Source IESE
10 / 100

A private equity client owns a specialized pharma manufacturer called OncoCo which focuses on cancer treatments. OncoCo is not only profitable, but also experienced steady growth in the past years. Hence, the PE fund was surprised when the management board of OncoCo stated that they expect declining profits in the future. OncoCo’s management board has also suggested, to cushion the decline with the acquisition of an additional asset. In particular, OncoCo’s board received the opportunity to purchase the commercial rights of liquid morphine.

The PE fund has asked us to figure out why a decline is expected and whether they should move forward with the acquisition.

Clarifying Information

  1. PE target: EBITDA margin > 20%
  2. Liquid Morphine: Used to treat severe pain, for example after an operation or a serious injury, or pain from cancer or a heart attack. Morphine liquid is fast acting and used for pain which is expected to last for a short time, e.g. when you start taking other forms of morphine to help find the right dose. Usually morphine is prescribed by pain specialists
  3. Commercial rights means that OncoCo will be able to produce and sell the product under its name. Often pharma companies purchase existing stocks and have the opportunity to either renegotiate the contracts with raw material suppliers or continue under existing conditions
  4. Declining revenue: expect a drop in revenues of 100m€
  5. BM: OncoCo’s income stems from one drug to treat a very niche, late stage cancer
  6. Price (treatment costs) per year: 10k€
  7. Location: EU
Mock Interview
Interviewer

A private equity client owns a specialized pharma manufacturer called OncoCo which focuses on cancer treatments. OncoCo is not only profitable, but also experienced steady growth in the past years. Hence, the PE fund was surprised when the management board of OncoCo stated that they expect declining profits in the future. OncoCo's management board has also suggested, to cushion the decline with the acquisition of an additional asset. In particular, OncoCo's board received the opportunity to purchase the commercial rights of liquid morphine. The PE fund has asked us to figure out why a decline is expected and whether they should move forward with the acquisition.

You

Thanks. Before analyzing, I'd like to clarify a few key questions...

Interviewer

Good question. Let me provide some background information...

You

Based on this, I suggest analyzing from these dimensions...

AI Score
Structure Analysis Communication Business Sense Quantitative
Practicing...
Score coming soon
Practice this case with AI Mock Interview

OncoCo, a niche cancer drug manufacturer facing 2/3 revenue decline due to patent expiration, considers acquiring liquid morphine commercial rights. While the target shows 32% EBITDA margins (above the 20% PE target), the recommendation is to decline due to business model incompatibility, operational challenges, and opioid crisis reputational risks.

Key Insights:

  1. Always diagnose the root cause first: OncoCo’s decline stems from patent expiration and generic entry, not market issues
  2. Financial metrics alone are insufficient for M&A decisions: 32% EBITDA margins are attractive but mask operational and strategic misalignment
  3. Business model fit is critical: OncoCo specializes in niche, high-price products while morphine is a mass-market commodity requiring different capabilities
  4. Reputational and regulatory risks must be weighed: The opioid crisis creates long-term enterprise value risk despite near-term profitability
  5. Market positioning matters: Target asset as category leader with 25% liquid morphine market share could theoretically grow to 40% to replace lost OncoCo profits, but this requires validating achievability